세계의 α-글루코시다아제 억제제 시장 : 시장 규모 분석(약제 종류별, 적응증별, 종류별, 유통 채널별, 지역별) 및 예측(2022-2032년)

Global Alpha-glucosidase Inhibitors Market is valued approximately at USD 3.3 billion in 2023 and is anticipated to grow with a steady compound annual growth rate of more than 3.20% over the forecast period 2024-2032. Alpha-glucosidase inhibitors (AGIs), a critical pharmacological class for glycemic control, have emerged as frontline agents for managing postprandial hyperglycemia in patients with Type 2 Diabetes Mellitus and pre-diabetes. These inhibitors delay the digestion of carbohydrates in the small intestine, thereby flattening blood sugar spikes post meals. The demand for AGIs has steadily increased as they are increasingly incorporated into multi-drug treatment regimens and are particularly effective for patients with carbohydrate-rich diets, especially in developing nations. The global alpha-glucosidase inhibitors market is advancing within the broader paradigm of personalized diabetes management and lifestyle-centric therapeutic strategies.

The market's momentum is primarily driven by the exponential rise in diabetes incidence globally, coupled with a shift toward preventive pharmacotherapy in pre-diabetic populations. In addition, generic formulations are becoming more prevalent, enhancing affordability and broadening market penetration. As patients and clinicians increasingly embrace polytherapy approaches, AGIs are often prescribed in combination with metformin or DPP-4 inhibitors, further reinforcing their relevance in contemporary diabetes care. Regulatory support for diabetic healthcare infrastructure, national screening programs, and digital health monitoring platforms is also facilitating better disease detection and earlier intervention, thereby supporting AGI market growth.

Nonetheless, certain headwinds are restraining growth. AGIs often face patient non-compliance due to gastrointestinal side effects, especially flatulence and diarrhea, which can affect long-term adherence. Moreover, newer classes of antidiabetic drugs with cardiovascular benefits-like SGLT2 inhibitors and GLP-1 receptor agonists-are increasingly capturing clinician preference in advanced stages of diabetes. However, for newly diagnosed patients, especially those with mild to moderate glucose intolerance, AGIs remain a safe, low-cost, and effective first-line or adjunctive therapy. Continuous efforts are also underway to improve AGI formulations to reduce adverse effects and enhance tolerability.

Retail and online pharmacy distribution channels are reshaping drug accessibility, particularly for chronic conditions requiring ongoing therapy such as diabetes. As oral tablets dominate the dosage form of AGIs, patients benefit from convenience, easy storage, and self-administration. E-commerce platforms and mail-order pharmacies are optimizing medication adherence with auto-refill programs and discounts. Meanwhile, branded drug manufacturers are increasingly investing in patient support initiatives and co-pay assistance to maintain competitive positioning against the growing wave of generics. These evolving strategies underscore the market's transition toward value-based, patient-centric delivery models.

From a regional perspective, Asia Pacific accounts for the largest share in the global alpha-glucosidase inhibitors market, led by countries such as India, China, and Japan-where high-carbohydrate diets and rapid urbanization are exacerbating diabetes prevalence. North America and Europe, though saturated in terms of branded drug uptake, continue to see steady demand driven by aging populations and rising obesity rates. Latin America and the Middle East & Africa are projected to register a gradual upsurge, supported by expanding healthcare access, growing awareness campaigns, and government initiatives focused on early diabetes intervention.

Major market player included in this report are:

• Bayer AG
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Glenmark Pharmaceuticals
• Cipla Inc.
• Novartis AG
• Sanofi S.A.
• Astellas Pharma Inc.
• Johnson & Johnson
• Merck & Co., Inc.
• Biocon Ltd.
• Dr. Reddy's Laboratories
• Abbott Laboratories

The detailed segments and sub-segment of the market are explained below:

By Drug Type

• Acarbose
• Miglitol
• Voglibose

By Indication

• Type 2 Diabetes Mellitus
• Pre-diabetes

By Type

• Branded
• Generic

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Alpha-glucosidase Inhibitors Market Executive Summary

• 1.1. Global Alpha-glucosidase Inhibitors Market Size & Forecast (2022-2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Drug Type
  • 1.3.2. By Indication
  • 1.3.3. By Type
  • 1.3.4. By Distribution Channel
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Alpha-glucosidase Inhibitors Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory Frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Alpha-glucosidase Inhibitors Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Surge in Global Diabetes Prevalence
  • 3.1.2. Preventive Pharmacotherapy Adoption in Pre-diabetes
  • 3.1.3. Growing Penetration of Generics Enhancing Affordability
• 3.2. Market Challenges
  • 3.2.1. Patient Non-compliance Due to Gastrointestinal Side Effects
  • 3.2.2. Competition from SGLT2 and GLP-1 Therapies
  • 3.2.3. Adherence Barriers in Chronic Regimens
• 3.3. Market Opportunities
  • 3.3.1. Novel Formulations to Mitigate Adverse Effects
  • 3.3.2. Digital Health Platforms for Therapy Monitoring
  • 3.3.3. Combination Therapy Strategies with Metformin and DPP-4 Inhibitors

Chapter 4. Global Alpha-glucosidase Inhibitors Market Industry Analysis

• 4.1. Porter's 5 Forces Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's Model
  • 4.1.7. Porter's 5 Forces Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economic
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top Investment Opportunities
• 4.4. Top Winning Strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspectives
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Alpha-glucosidase Inhibitors Market Size & Forecasts by Drug Type (2022-2032)

• 5.1. Segment Dashboard
• 5.2. Acarbose: Revenue Trend Analysis, 2022 & 2032
• 5.3. Miglitol: Revenue Trend Analysis, 2022 & 2032
• 5.4. Voglibose: Revenue Trend Analysis, 2022 & 2032

Chapter 6. Global Alpha-glucosidase Inhibitors Market Size & Forecasts by Indication (2022-2032)

• 6.1. Segment Dashboard
• 6.2. Type 2 Diabetes Mellitus: Revenue Trend Analysis, 2022 & 2032
• 6.3. Pre-diabetes: Revenue Trend Analysis, 2022 & 2032

Chapter 7. Global Alpha-glucosidase Inhibitors Market Size & Forecasts by Type (2022-2032)

• 7.1. Segment Dashboard
• 7.2. Branded: Revenue Trend Analysis, 2022 & 2032
• 7.3. Generic: Revenue Trend Analysis, 2022 & 2032

Chapter 8. Global Alpha-glucosidase Inhibitors Market Size & Forecasts by Distribution Channel (2022-2032)

• 8.1. Segment Dashboard
• 8.2. Hospital Pharmacies: Revenue Trend Analysis, 2022 & 2032
• 8.3. Retail Pharmacies: Revenue Trend Analysis, 2022 & 2032
• 8.4. Online Pharmacies: Revenue Trend Analysis, 2022 & 2032

Chapter 9. Global Alpha-glucosidase Inhibitors Market Size & Forecasts by Region (2022-2032)

• 9.1. North America Market
  • 9.1.1. U.S. Market
  • 9.1.2. Canada Market
• 9.2. Europe Market
  • 9.2.1. UK Market
  • 9.2.2. Germany Market
  • 9.2.3. France Market
  • 9.2.4. Spain Market
  • 9.2.5. Italy Market
  • 9.2.6. Rest of Europe Market
• 9.3. Asia Pacific Market
  • 9.3.1. China Market
  • 9.3.2. India Market
  • 9.3.3. Japan Market
  • 9.3.4. Australia Market
  • 9.3.5. South Korea Market
  • 9.3.6. Rest of Asia Pacific Market
• 9.4. Latin America Market
  • 9.4.1. Brazil Market
  • 9.4.2. Mexico Market
• 9.5. Middle East & Africa Market
  • 9.5.1. Saudi Arabia Market
  • 9.5.2. South Africa Market
  • 9.5.3. Rest of Middle East & Africa Market

Chapter 10. Competitive Intelligence

• 10.1. Key Company SWOT Analysis
  • 10.1.1. Bayer AG
  • 10.1.2. Pfizer Inc.
  • 10.1.3. Takeda Pharmaceutical Company Limited
• 10.2. Top Market Strategies
• 10.3. Company Profiles
  • 10.3.1. Bayer AG
    • 10.3.1.1. Key Information
    • 10.3.1.2. Overview
    • 10.3.1.3. Financial (Subject to Data Availability)
    • 10.3.1.4. Product Summary
    • 10.3.1.5. Market Strategies
  • 10.3.2. Sun Pharmaceutical Industries Ltd.
  • 10.3.3. Teva Pharmaceutical Industries Ltd.
  • 10.3.4. Glenmark Pharmaceuticals
  • 10.3.5. Cipla Inc.
  • 10.3.6. Novartis AG
  • 10.3.7. Sanofi S.A.
  • 10.3.8. Astellas Pharma Inc.
  • 10.3.9. Johnson & Johnson
  • 10.3.10. Merck & Co., Inc.
  • 10.3.11. Biocon Ltd.
  • 10.3.12. Dr. Reddy's Laboratories
  • 10.3.13. Abbott Laboratories

Chapter 11. Research Process

• 11.1. Research Process
  • 11.1.1. Data Mining
  • 11.1.2. Analysis
  • 11.1.3. Market Estimation
  • 11.1.4. Validation
  • 11.1.5. Publishing
• 11.2. Research Attributes